Goncalves Joana 4

What Happened Joana Goncalves, Chief Medical Officer of Oruka Therapeutics (ORKA), exercised options to acquire 7,000 shares (two exercises of 3,500 shares each) and sold a total of 7,000 shares in open-market transactions on April 15, 2026. The exercises were at strike prices of $6.84 (3,500 shares; $23,940) and $7.80 (3,500 shares; $27,300) for a combined cost of $51,240. The open-market sales comprised 4,227 shares at a weighted average ~$65.73 (proceeds $277,837), 2,273 shares at a weighted average ~$66.56 (proceeds $151,301), and 500 shares at a weighted average ~$67.38 (proceeds $33,692), for total proceeds of ~$462,830. The filing also reports two related derivative-conversion line items recorded at $0 (bookkeeping entries related to conversion/exercise).

Key Details

• Transaction date: April 15, 2026.
• Exercises acquired: 7,000 shares (3,500 @ $6.84; 3,500 @ $7.80). Total exercise cost: $51,240.
• Shares sold: 7,000 shares in multiple trades; total gross proceeds ≈ $462,830.
• Reported sale price ranges (weighted averages noted in footnotes):
  • 4,227 shares: multiple prices $65.31–$66.29 (weighted avg $65.73).
  • 2,273 shares: multiple prices $66.31–$67.15 (weighted avg $66.56).
  • 500 shares: multiple prices $67.35–$67.41 (weighted avg $67.38).
• Sales were made pursuant to a Rule 10b5-1 trading plan established Sept 19, 2025 (Footnote F1).
• Vesting info (from filing footnotes): related option and warrant vest 1/4 on Apr 18, 2025 and 1/48 monthly thereafter (F5, F6).
• Shares owned after the transactions: not disclosed in the provided filing.
• Filing timeliness: Report appears filed the same day (Apr 15, 2026); no late filing indicated.

Context

• This sequence (exercise of low‑strike options followed by immediate open‑market sales) often reflects executives monetizing vested option shares; the filing shows acquisition cost ($51K) vs. sale proceeds ($463K). The sales were executed under a pre-established 10b5-1 plan, which is a preauthorized trading arrangement and commonly used to avoid questions about timing.
• The $0 disposals labeled as derivative conversions are reporting mechanics tied to exercising/converting instruments (they do not represent cash proceeds).
• As always, these filings are factual disclosures of transactions and do not, by themselves, indicate the insider’s view of the company’s prospects.